Arylhydrazinopyrimidines inhibit DNA synthesis in Bacillus subtilis by promoting formation of a specific, long-lived ternary complex with DNA polymerase III and the template-primer DNA. DNA polymerase III contains an associated, single-strand-selective exonuclease which generates 5'-mononucleotides. Drug inhibition of the nuclease similarly proceeds through formation of the ternary complex. The ternary complex was isolated by agarose chromatography. Like inhibition of the nuclease, optimum formation of the complex requires duplex DNA with single-stranded regions such as bacteriophage X DNA (purely single-and double-stranded DNA are ineffective) and is antagonized by specific deoxyribonucleoside triphosphates. Formation of the ternary complex requires a di-or polyvalent cation and is inhibited by sulfhydryl reagents and high ionic strength. The complex dissociates with a half-life of the order of minutes at 4°.
negative bacteria, but not Escherichia coli (ref. 2; S. Lerner, personal communication). In Bacillus 8ubtilis the hydrazino derivatives of these drugs selectively arrest DNA synthesis through their action on DNA polymerase III (3) (4) (5) . Purified B. subtilis DNA polymerase III is highly sensitive to the drugs, unlike the other B. tubtili8 DNA polymerases and E. coli polymerases (3) (4) (5) . Proof that DNA polymerase III is the target for the drug in vivo was provided by isolation of drugresistant mutants which produce a drug-resistant polymerase III (6, 7) . Some of these mutants also are conditionally lethal and have an elevated mutation rate, in accord with a central role of polymerase III in DNA replication (7) .
We suggested a simple but specific molecular mechanism for drug inhibition (3), which is illustrated in Fig. 1 for 6-(phydroxyphenylhydrazino)uracil [OHPh (NH)2UraI. The scheme postulates that the OHPh(NH)2Ura forms a thermodynamically favored, reversible ternary complex with polymerase III and a template cytosine residue at the template-primer active center. The related drug 6-(p-hydroxyphenylhydrazino)isocytosine [OHPh(NH)2Iso] is postulated to bond specifically to template thymine residues. The drugs form hydrogen bonds with the template and overlap the deoxyribonucleoside triphosphate binding site of the enzyme.
Abbreviations: OHPh(NH)2Ura, 6 -(p-hydroxyphenylhydrazino)-uracil; OHPh(NH)2Iso, 6-(p-hydroxyphenylhydrazino)isocytosine; EDTA, ethylenediaminetetraacetate.
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The ternary complex dissociates slowly and the enzyme is thus effectively trapped in an inactive state.
Several lines of evidence led to this postulated mechanism (3). First, OHPh(NH)2Ura inhibition was selectively and competitively antagonized by dGTP and dITP. Since presumably the polymerase will bind only dGTP or dITP when cytosine is the next base to be copied, the specificity of attenuation is explained. Attenuation of OHPh(NH)21so inhibition was specific for dATP. Second, polymerization directed by an adenine-containing template was inhibited by neither drug, while that directed by an adenine-and thymine-containing template was inhibited only by OHPh(NH)2Iso. Third, the individual incorporation of all four deoxyribonucleoside triphosphates was inhibited. Fourth, while the oligo(dT) poly(dA)-directed incorporation of dTTP was insensitive to high concentrations of the drug, the addition of a minute amount of gapped DNA permitted full inhibition. Thus, the formation of the ternary complex efficiently scavenged free enzyme in the presence of a large excess of potential priming sites. In light of this effect, the model will be referred to as ternary scavenging.
This report describes the drug inhibition of an exonuclease intrinsic to DNA polymerase III and the isolation of the inhibitory ternary complex. The study reveals the requirements for ternary complex formation and provides strong support for the inhibition scheme.
MATERIALS AND METHODS
Unless otherwise specified, materials and experimental procedures were as described previously (3, 7) .
Nucleotides and Nucleic Acid8. Poly(U) was purchased from Miles Laboratories and 5'-and 3'-dTMP from P. L. Biochemicals. Salmon testes DNA digested with DNase I until 2% of the material absorbing at 260 nm became acid-soluble (7), which contains nicks and gaps of various lengths, is referred to as "gapped DNA." The gapped DNA was separated from low molecular weight material by Sepharose 2B filtration. Bacteriophage DNA was obtained by phenol extraction of purified virions. Phage X CI857 DNA was provided by R. Gayda. T7, X, and N4 (8) DNA contained less than one single-strand break per molecule as judged by analytical sedimentation in alkali (9) . External 3'-hydroxyl terminated gaps were introduced into N4 DNA by digestion with exonuclease III (10) RESULTS DNA Polymerase III Has an Associated Exonuclease. Extensive purification of B. subtilis DNA polymerase III revealed an associated nuclease activity which co-chromatographed with polymerase activity on hydroxylapatite-the final step in the purification. The enzyme purified by hydroxylapatite was used in all subsequent experiments. Under optimal conditions for each activity the polymerase is about six times more active than the nuclease. Like polymerase III activity (7), the nuclease is inhibited more than 95% by 8 mM N-ethylmaleimide, has a pH optimum near pH 7.5, and has sharply reduced activity at high ionic strength; 100 mM KCl inhibits 90%. To define more precisely the DNA requirement for ternary complex formation, we employed homogeneous preparations of DNA from several bacteriophages ( Table 1) . Intact duplex N4 and T7 DNA, even at 170 MM, did not promote inhibition of the nuclease. However, terminally gapped N4 DNA generated by exonuclease III treatment and, even more impressively, phage A DNA, which contains natural 3'-hydroxylterminated gaps and a template cytosine residue adjacent to one primer terminus (16), were quite effective. T5 DNA, containing about five naturally occurring nicks (17) , and T7 DNA containing about four DNase-I-generated nicks were less effective than X DNA; but at higher nicked DNA concentrations inhibition ensued, perhaps after fraying or nucleolytic enlargement of the nicks. Thus, double-stranded DNA, single-stranded DNA, and double-stranded ends of DNA do not permit ternary complex formation; 3'-hydroxyl-terminated breaks are required.
Isolation of the Ternary Complex by Gel Filtration. A prediction of the inhibition mechanism depicted in Fig. 1 is that OHPh(NH)2Ura and OHPh(NH)21so will potentiate the binding of I)NA polymerase III to its DNA substrate. To test this prediction, we preincubated the enzyme with 40 uM gapped DNA and 5 MM M9gCl, in the presence and absence of 25 uM OHPh(NH)2Ura, and then passed it over a Sepharose 4B column. Without drug, the enzyme was included into the gel, eluting in a rather broad zone but well separated from the void volume where the gapped DNA eluted (Fig. 3) . However, with OHPh (NH)2Ura in the column and preincubation buffers, the enzyme as measured both by its polymerase and its exonuclease activity was now excluded by the gel in a sharp band (Fig. 3) . At a high gapped DNA concentration (400 MAM), the polymerase is largely excluded even without the drug. This binding is not seen with intact phage DANA. As documented below, the drugs appear to potentiate the binding of enzyme to DNA that is the prerequisite for polymerization.
Requirements for Ternary Complex Formation. The requirements for formation of the ternary complex were determined [ by the agarose column procedure. Essentially the same chromatographic profile was obtained from 10 to 100 AM OHPh(NH)2Ura; however, when the drug concentration was lowered to 1 MM in the preincubation and column buffers, about one-half of the enzyme was excluded. Therefore, only a low concentration of drug, of the same magnitude as the kinetically determined Ki (3), is needed for complex formation.
Omitting OHPh(NH)2Ura or DNA from the preincubation mixture abolished complex formation, as did replacement of OHPh(NII)2Ura by the azo form of the drug. OHPh(NH)2Iso can substitute for OHPh (NH)2Ura.
The amount of complex recovered is somewhat sensitive to high ionic strength but less so than polymerase and nuclease activity. The amount of enzyme eluting by fraction 10 (see Fig. 3 Mg++ affects strongly the binding of DNA polymerase III to its DNA substrate. In the absence of both drug and MgCl2, with and without 0.6 mM EDTA, the enzyme chromatographic profile was smeared into the void volume (47% elutes by fraction 10). The addition of drug caused only slightly more enzyme to be excluded, about 58%. Thus, Mg++ apparently inhibits binding of polymerase to DNA in the absence of drug but is required for ternary complex formation. This is not an ionic strength effect. In the absence of MgC12, OHPh(NIi)2Ura had little effect on the chromatographic profile of the enzyme at 50-75 mM phosphate buffer, and 2 mM MgCl2 suffices in promoting formation of the ternary complex. The effect of Mg4-+ is not totally specific, howvever, since with 3 mM spermidine and 0.15 mM EI)TA but no Mg++, 50 MM OHPh(NH)2Ura increased the void volume fraction of enzyme from 25 to 65%; in the control with drug and 2 mM MgCl2, 80% was excluded. In polymerase but not in exonuclease assays, 3 complex, like polymerase activity, requires a divalent or polyvalent cation.
The formation of the ternary complex is inhibited by sulfhydryl reagents, as is polymerase and nuclease activity. With 0.1 mM p-chloromercuriphenylsulfonic acid, a reversible inhibitor, in the preincubation and column buffers, OHPh(NH)2Ura did not promote complex formation.
Isolation of the ternary complex by agarose chromatography has the same DNA requirement as scavenging of the nuclease shown in Table 1 (Fig. 4) . The data in Fig. 4 also show that the formation of the ternary complex is reversible, as is drug inhibition of polymerase activity (3) .
An independent measurement of the stability of the ternary complex was made by means of kinetics. The relief of OHPh-(NH)2Ura inhibition of polymerase activity by dGTP is not immediate (Fig. 5) but follows a lag averaging 50 sec at 100 in three determinations. The controls shown are for the addition of dGTP in the absence of drug and the addition of dATP in its presence; no effect of the nucleotides was seen. If the decay of ternary complex is first order, then this 50-sec lag corresponds to a half-life of 35 sec. The reasons for this approximately 5-fold difference in the physical and kinetic estimates of stability of the ternary complex are not known, but the conditions of the experiments and the assumptions in the calculations are quite different. However, both determinations imply that the half-life of the complex at 40 is of the order of minutes, and therefore confirm the prediction of the scavenging model that the ternary complex dissociates slowly.
DISCUSSION
Several lines of evidence suggest that B. subtilis DNA polymerase III contains an intrinsic exonuclease. The activities copurify, co-chromatograph within experimental error on Sepharose 4B in the presence and absence of OHPh(NH)2Ura (Fig. 3) , and are similarly inhibited by N-ethylmaleimide, high ionic strength, and arylhydrazinopyrimidines. OHPh-(NH)2Ura inhibition of both activities requires templateprimer DNA and is selectively attenuated by dGTP.
The nuclease and gel filtration experiments provide strong support for the ternary complex scavenging mechanism for arylhydrazinopyrimidine inhibition. First, the drugs do not act simply by starving the enzyme of a specific deoxyribonucleoside triphosphate, since inhibition of the nuclease and formation of the ternary complex as monitored by agarose chromatography occur in the absence of deoxyribonucleoside triphosphates. Second, only a template-primer for the polymerase permits isolation of the ternary complex by gel filtration and drug inhibition of the nuclease. The failure of singlestranded DNA to form the stable ternary complex is particularly revealing, since it contains cytosine residues and is the preferred nuclease substrate. Therefore, OHPh (NH)2Ura strengthens only one specific mode of binding of the enzyme to DNA, namely that which leads to polymerization. If the single-stranded nuclease substrate binds like a primer strand, then OHPh(NH)2Ura bound in the deoxyribonucleoside triphosphate binding site cannot bind simultaneously to a cytosine residue as required by the ternary scavenging scheme.
Third, the proposition that the drugs bind to specific template residues is strengthened, since inhibition of the nuclease and the formation of the ternary complex are attenuated selectively by dGTP and dATP for OHPh (NH)2Ura and OHPh(NH)2Iso, respectively. The base specificity of deoxyribonucleoside triphosphate attenuation and the strict requirement for a primer terminus imply that the drug binds in the enzyme's deoxyribonucleoside triphosphate binding site and to the specific template residue adjacent to the primer terminus rather than to other sites on the enzyme and template.
Fourth, the stability of the ternary complex is shown both by the slow breakdown of the complex on agarose gels (Fig. 4) and by the lag in reversal of polymerase inhibition by dGTP (Fig. 5) . The longer half-life measured by the former method may be an overestimate, since it assumes that all void volume activity still retains drug and that the dissociation of the enzyme-DNA binary complex occurs instantaneously. Both methods indicate a half-life of dissociation at 40 of the order of minutes. This rate is orders of magnitude slower than our estimate for the turnover number of the polymerase. Also, the catalytic complex of enzyme, DNA, and nucleoside triphosphate must be less stable than the inhibitory ternary complex, since dGTP has no detectable effect on the agarose profile of the enzyme. The inhibition scheme suggests two explanations for the slow breakdown. First, the binding of the phenol moiety of the drug to the enzyme, an interaction not shared with deoxyribonucleoside triphosphate substrates, may be only slowly reversible. Second, perhaps nucleotide incorporation, not occurring in the ternary complex, facilitates enzyme release from the DNA.
The discussion has implicitly assumed that the chromatographic and inhibitory complexes are identical, because isolation of the polymerase in the agarose void volume has the same requirements as inhibition. The agarose complex requires only low concentrations of drug, of a similar magnitude to the Ki, and both OHPh(NH)2Ura and OHPh(NH)2Iso suffice. Formation of the complex is reversible, and is attenuated by the same deoxyribonucleoside triphosphates that antagonize inhibition. The DNA structural requirements for the drug-promoted exclusion of enzyme and for inhibition are the same.
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